Filing Details
- Accession Number:
- 0001209191-15-036748
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2015-04-28 18:09:47
- Reporting Period:
- 2015-04-24
- Filing Date:
- 2015-04-28
- Accepted Time:
- 2015-04-28 18:09:47
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1509190 | Aratana Therapeutics Inc. | PETX | Pharmaceutical Preparations (2834) | 383826477 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1336284 | Linda Rhodes | C/O Aratana Therapeutics, Inc. 1901 Olathe Boulevard Kansas City KS 66103 | Chief Scientific Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2015-04-24 | 17,200 | $0.00 | 438,205 | No | 4 | A | Direct | |
| Common Stock | Disposition | 2015-04-27 | 11,700 | $14.78 | 426,505 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2015-04-27 | 3,300 | $15.78 | 423,205 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | A | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2014.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.47 to $15.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2014. This sale constitutes the final sale under such trading plan.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.52 to $16.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Billionaire Hedge Funds
